Clinical trialNCT06657144RecruitingPhase 1Interventional

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

SponsorCoherus Oncology, Inc.Enrollment154Advanced Solid TumorMetastatic Solid Tumor

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Study Director
Coherus Oncology
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Taiwan

Changhua Christian Hospital
Chang-hua, Taiwan
Kuan-Ming Lai, MD
Recruiting
E-Da Cancer Hospital
Kaohsiung City, Taiwan
Meng-Che Hsieh, MD
Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Jaw-Yuan Wang, MD
Recruiting
China Medical University Hospital
Taichung, Taiwan
Li-Yuan Bai, MD, PhD
Recruiting
Taichung Veterans General Hospital
Taichung, Taiwan
Hsin-Chen Lin, MD
Recruiting
Chi Mei Hospital
Tainan, Taiwan
Chien-Liang Lin, MD
Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan
Chia-Jui Yen, MD
Recruiting
Mackay Memorial Hospital
Taipei, Taiwan
Nai-Wen Su, MD
Recruiting
National Taiwan University Hospital
Taipei, Taiwan
Chia-Chi Lin, MD
Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan
Ming-Huang Chen, MD
Recruiting

United States

the University of Arizona Cancer Center
Tucson, Arizona, United States
Withdrawn
City of Hope
Duarte, California, United States
Dani Castillo, MD
Recruiting
University of Colorado - Aurora Cancer Center
Aurora, Colorado, United States
Sunnie Kim, MD
Recruiting
Winship Cancer Center - Emory University
Atlanta, Georgia, United States
Oluwadunni Emiloju, MD
Recruiting
Ochsner Health
New Orleans, Louisiana, United States
Jonathan Mizrahi, MD
Recruiting
Henry Ford Health System
Detroit, Michigan, United States
Gazala Khan, MD
Recruiting
Comprehensive Cancer Center of Nevada
Las Vegas, Nevada, United States
Kyaw Thein, MD
Recruiting
Christus St Vincent Regional Medical Center
Santa Fe, New Mexico, United States
Andrea Teague, MD
Recruiting
Start New York
Lake Success, New York, United States
Geraldine O'Sullivan Coyne, MD
Recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, United States
Yelena Janjigian, MD
Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Dan Feng, MD
Recruiting
University of Pittsburg Medical Center _upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Anwaar Saeed, MD
Recruiting
Prisma Health Cancer Institute
Greenville, South Carolina, United States
Ki Chung, MD
Recruiting
Scri Oncology Partners
Nashville, Tennessee, United States
Meredith S Pelster, MD
Recruiting
Texas Oncology - Central South
Austin, Texas, United States
Vivian Cline, MD
Recruiting
Start San Antonio, Llc.
San Antonio, Texas, United States
Amita Patnaik, MD
Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Christopher Nevala-Plagemann, MD
Recruiting
Start Mountain Region, Llc.
West Valley City, Utah, United States
William McKean, MD
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Mohamad A Salkeni, MD
Recruiting
Virginia Oncology Associates
Norfolk, Virginia, United States
Withdrawn

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fluorouracil →CHS-114Cisplatin →Toripalimab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Apr 2025
Primary completion: 31 Jan 2028
Completion: 31 Jan 2028
Last update posted: 15 Jul 2026
Registered enrollment: 154
Registry id: NCT06657144

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.